Results 211 to 220 of about 72,887 (326)

Retrospective Analysis of <i>BRCA</i>-Altered Uterine Sarcoma Treated With Poly(ADP-ribose) Polymerase Inhibitors. [PDF]

JCO Precis Oncol
Rao M, Merrill M, Troxel M, Chiang S, Momeni-Boroujeni A, Hensley ML, Schram AM.   +6 more
europepmc   +1 more source

RAD21 Confers Poor Prognosis and Affects Ovarian Cancer Sensitivity to Poly(ADP-Ribose)Polymerase Inhibitors Through DNA Damage Repair. [PDF]

Front Oncol, 2022
Gou R, Li X, Dong H, Hu Y, Liu O, Liu J, Lin B.   +6 more
europepmc   +1 more source

Aging‐Derived Alterations in Genomic, Immune, and Metabolic Networks: Implications for Cancer Development and Therapy

MedComm – Oncology, Volume 5, Issue 1, March 2026.
Ageing acts as a double‐edged sword in cancer. In the elderly, open chromatin, immunosenescence, and chronic inflammation drive SASP (IL‐6, MMPs), MDSC accumulation and T‐cell suppression, fostering tumor‐promoting microenvironments and limited therapeutic benefit.
Qi Wang, Xue Sun, Xinhao Han, Xingda Zhang, Wenzheng Wang, Hongbin Wang, He Ren, Lina Gu   +7 more
wiley   +1 more source

Efficacy and safety of poly ADP-ribose polymerase inhibitors (PARPis) in extensive-stage small-cell lung cancer (ES-SCLC) treatment: a systematic review and meta-analysis. [PDF]

J Thorac Dis
Cheng CC, Ma LJ, Pang XM, Huang TS, Wang MF, Xu JY, Wang RQ, Chen X, Sun K, Zhao WX, Yan M, Wang P.   +11 more
europepmc   +1 more source

Comparative Efficacy and Safety of Poly (ADP-Ribose) Polymerase Inhibitors in Patients With Ovarian Cancer: A Systematic Review and Network Meta-Analysis. [PDF]

Front Oncol, 2022
Luo J, Ou S, Wei H, Qin X, Jiang Q.
europepmc   +1 more source

Genetic Testing Among Black and White Patients With Advanced Prostate Cancer: A Retrospective Analysis of Testing Utilization and Referral Patterns

The Prostate, Volume 86, Issue 4, Page 440-450, March 2026.
ABSTRACT Purpose Genetic testing is recommended but underutilized in advanced prostate cancer. Given known disparities affecting Black patients, we assessed genetic testing completion rates by race. Methods Henry Ford Health's electronic medical record was queried for new prostate cancer diagnoses (1/1/2017–6/30/2022).
Kyle C. McElyea, James P. Purtell, Avery K. Supernois, Courtney M. Rose, Farhan Ibrahim, Mohammed A. Baseer, Sunita Ghosh, Clara Hwang   +7 more
wiley   +1 more source

Poly(ADP-ribose) polymerase (PARP) inhibitors for BRCA-associated early triple-negative breast cancer: progress and future hopes

Sh. R. Abdullaeva, Т. Yu. Semiglazova, A. S. Artemyeva, Татьяна Ивановна Севостьянова, Л. В. Филатова, В. В. Семиглазов, Petr Krivorotko, Semiglazov Vf   +7 more
openalex   +1 more source

Altering Nitrogen Heterocycles of AZD2461 Affords High Affinity Poly(ADP-ribose) Polymerase-1 Inhibitors with Decreased P-Glycoprotein Interactions

, 2018
Sean W. Reilly, Laura N. Puentes, Chia‐Ju Hsieh, Mehran Makvandi, Robert H. Mach   +4 more
openalex   +1 more source

Novel clinical potential of poly (ADP‑ribose) polymerase inhibitors in triple‑negative breast cancer: Mechanistic insights and clinical applications (Review). [PDF]

Oncol Lett
Han Y, Wei L.
europepmc   +1 more source

Corrigendum: Myelodysplastic syndrome/acute myeloid leukemia following the use of poly-ADP ribose polymerase inhibitors: A real-world analysis of postmarketing surveillance data. [PDF]

Front Pharmacol, 2022
Zhao Q, Ma P, Fu P, Wang J, Wang K, Chen L, Yang Y.   +6 more
europepmc   +1 more source